Kategori: ASO

Start af rekruttering til det kliniske ATTUNE-forsøg

ATTUNE-forsøget er et klinisk fase 1/2-studie sponsoreret af Ionis. Det har til formål at evaluere ION440, en undersøgende antisense-oligonukleotid (ASO)-behandling, der er designet til at adressere den grundlæggende årsag til MECP2 Duplication Syndrome (MDS).

ION440: IONIS bringer MDS-fællesskabet op på næste niveau

Written by David and verified by Ionis Following Ionis’ recent announcement about the upcoming clinical trial, we aim to provide a clearer understanding of this trial. It is especially important for families considering enrolling their child to know what a clinical trial is, particularly in the context of rare diseases like MECP2 Duplication Syndrome (MDS). […]